Thyroid hormone receptor agonists - Pipeline Insight, 2024

This “Thyroid Hormone Receptor Agonists - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Thyroid Hormone Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Thyroid Hormone Receptor Agonists Understanding

Thyroid Hormone Receptor Agonists: Overview

Thyroid hormones have important effects on cellular development, growth, and metabolism and are necessary for the healthy function of almost all tissues. Hyperthyroid patients with excess thyroid hormone levels experience tachycardia, fatigue, muscle wasting, and osteoporosis. However, although high thyroid hormone levels have adverse effects, efforts have been made to harness the beneficial effects, such as reduced serum low-density lipoprotein (LDL) cholesterol levels, elevated basal metabolic rate, and weight loss.

Thyroid hormones interact with nuclear thyroid hormone receptors (TRs), and cholesterol levels are reduced through TRß, whereas extrahepatic adverse actions are primarily connected to TRa. Thus, to develop a useful compound for clinical use, efforts have been focusing on developing compounds with isomer-specific functions based on the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TRß specific.

Selective agonists of the beta isoform of thyroid hormone receptor (TRß) do not exhibit T3-induced cardiotoxicity and show a good safety profile in patients with NASH.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid Hormone Receptor Agonists R&D. The therapies under development are focused on novel approaches for Thyroid Hormone Receptor Agonists.

Thyroid Hormone Receptor Agonists Emerging Drugs Chapters

This segment of the Thyroid Hormone Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Thyroid Hormone Receptor Agonists Emerging Drugs

MGL-3196: Madrigal Pharmaceuticals MGL-3196 (Resmetirom) is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist. Preclinical, toxicology, Phase 1, and Phase 2 clinical data suggest resmetirom has an attractive, differentiated profile as a potential treatment for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and associated dyslipidemias.

It is currently in Phase III stage of development and is being developed by Madrigal Pharmaceuticals.

VK-2809: Viking Therapeutics VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.

It is currently in Phase II stage of development and is being developed by Viking Therapeutics.

Thyroid Hormone Receptor Agonists: Therapeutic Assessment

This segment of the report provides insights about the different Thyroid Hormone Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Thyroid Hormone Receptor Agonists

There are approx. 10+ key companies which are developing the Thyroid Hormone Receptor Agonists. The companies which have their Thyroid Hormone Receptor Agonists drug candidates in the most advanced stage, i.e. Phase III include, Madrigal Pharmaceuticals.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Thyroid Hormone Receptor Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Thyroid Hormone Receptor Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Thyroid Hormone Receptor Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid Hormone Receptor Agonists drugs.

Thyroid Hormone Receptor Agonists Report Insights

• Thyroid Hormone Receptor Agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Thyroid Hormone Receptor Agonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Thyroid Hormone Receptor Agonists drugs?
• How many Thyroid Hormone Receptor Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Thyroid Hormone Receptor Agonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Thyroid Hormone Receptor Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Thyroid Hormone Receptor Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Terns Pharmaceuticals
• Ascletis
• Autobahn Therapeutics
• Madrigal Pharmaceuticals
• Viking Therapeutics
• Egetis Therapeutics
• Aligos Therapeutics

Key Products

• TERN-501
• ASC-41
• ABX-002
• MGL-3196
• VK-2809
• Emcitate
• VK 0214
• ABX-003
• ALG-055009

This product will be delivered within 2 business days.